Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Elite provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dr. Ronald Sweren is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous lymphoma/mycosis fungoides, phototherapy/ photopheresis and melanoma. Dr. Sweren also serves as director of the Phototherapy/Photopheresis Program in the Department of Dermatology. Dr. Sweren earned his M.D. from the University of Maryland School of Medicine. He completed his residency in dermatology at University of Maryland Medical Center and in pediatrics at Sinai Hospital of Baltimore. Dr. Sweren is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Mycosis Fungoides, Cutaneous T-Cell Lymphoma (CTCL), Melanoma, and T-Cell Lymphoma.

Mei Tang is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma. Dr. Tang is currently accepting new patients.

Rebecca Dodson is a General Surgeon and a Surgical Oncologist in Baltimore, Maryland. Dr. Dodson has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Subareolar Abscess, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Hepatectomy. Dr. Dodson is currently accepting new patients.

Andrew Marek is a Dermatologist in Timonium, Maryland. Dr. Marek is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Trichoepithelioma, Multiple Familial Trichoepithelioma, and Syringoma. Dr. Marek is currently accepting new patients.

Dr. Amanda Nickles Fader is a professor in the Johns Hopkins Hospital Department of Gynecology and Obstetrics and the Sidney Kimmel Cancer Center. She is the former fellowship director and division director of the Johns Hopkins Kelly Gynecologic Oncology Service and currently is Vice Chair of Gynecologic Surgical Operations and the Director of the Center for Rare Gynecologic Cancers. Additionally, she serves as the 2024-2025 President of the Society of Gynecologic Oncology. Dr. Fader received her undergraduate degree with highest distinction in music (violin performance) and pre-medicine from the University of Virginia. She earned her medical degree from the Medical College of Virginia, and completed her residency in obstetrics and gynecology at the Magee-Women’s Hospital of UPMC in Pittsburgh. Dr. Fader then underwent gynecologic oncology fellowship training at the Cleveland Clinic. She has co-authored more than 230 publications in peer-reviewed medical journals and is recognized as an expert in rare gynecologic tumors, clinical trials and quality and safety in surgery. She has a special interest in uterine serous carcinoma and low-grade serous carcinoma of the ovary and currently serves as the PI or co-PI of three international NRG Oncology clinical trials. Dr. Fader serves as a national board examiner in gynecologic oncology for the American Board of Obstetrics and Gynecology and Associate Editor of the Gynecologic Oncology journal is a member of the Rare Tumor and Uterine Corpus Committees of the NRG/Gynecologic Oncology Group. She is also co-founder of the Society of Gynecologic Oncology BRIDGES Program, a two-year longitudinal clinical trials and career development program for early-career oncologists. She has been the recipient of several research grants and awards for her research, including the Society of Gynecologic Oncology Innovations Award, the Best AAGL Paper in Minimally Invasive Gynecologic Oncology Surgery, a Department of Defense Ovarian Cancer Clinical Trials Academy Leadership Award, and National Cancer Institute Cervical SPORE grant. Dr. Fader is consistently recognized for clinical excellence on lists such as Baltimore magazine’s Top Docs and Castle Connolly’s Top Doctors, and is a recipient of the Top 10 Docs, Compassionate Doctors and Patient Choice Awards from Vitals.com. She has particular expertise with the surgical and medical management of uterine (endometrial), ovarian, cervical and vulvar cancers, as well as the treatment of women who are at high risk for developing a gynecologic malignancy. She has a special interest in caring for patients throughout the entire spectrum of their lives: from preventive oncology — minimizing key risk factors that can lead to gynecologic cancers — to survivorship initiatives addressing all aspects of recovery, including emotional well-being, sexual health and clinical follow-up. Dr. Fader is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ovarian Cancer, Bladder Reconstruction, and Hernia Surgery.

Dr. Joel Sunshine is an Assistant Professor of Dermatology, Pathology, Oncology, and Biomedical Engineering at the Johns Hopkins University School of Medicine. He specializes in medical dermatology and skin cancer. His areas of clinical expertise include general dermatology, cutaneous oncology including melanoma and Merkel cell carcinoma, and supportive oncodermatology. Dr. Sunshine obtained his undergraduate degree from Brandeis University, his M.D. and Ph.D. from Johns Hopkins University School of Medicine, and his dermatology residency training and dermatopathology fellowship from the Northwestern University Feinberg School of Medicine. Dr. Sunshine is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Merkel Cell Carcinoma, Melanoma, Familial Atypical Multiple Mole Melanoma Syndrome, and Hidradenitis Suppurativa.

Meg Gerstenblith is a clinical associate in dermatology at the Johns Hopkins University School of Medicine, with a focus on general dermatology and melanoma. Dr. Gerstenblith has co-written over 35 peer-reviewed articles and more than 40 abstracts on dermatology and cutaneous oncology. She received her medical degree from the Johns Hopkins University School of Medicine, where she also completed her dermatology residency. Dr. Gerstenblith is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Focal Dermal Hypoplasia, Basal Cell Skin Cancer, and Pigmented Purpuric Dermatosis.

Dr. Elise Ng is as assistant professor of dermatology and the Director of Dermatologic Surgery in the Department of Dermatology at Johns Hopkins. She oversees the Johns Hopkins team of Mohs surgeons across four clinical sites, including the Johns Hopkins Outpatient Center, Greenspring Station, the Medical Pavilion at Howard County, and Sibley Memorial Hospital. She also serves as the Director of the Johns Hopkins Micrographic Surgery and Dermatologic Oncology Fellowship training program and is the clinical co-director of the Melanoma Program at the Sidney Kimmel Comprehensive Cancer Center. Her areas of clinical expertise include Mohs micrographic surgery, complex facial reconstruction following skin cancer surgery, melanoma, cosmetic scar revision, and surgical management of benign and malignant skin lesions. Dr. Ng graduated magna cum laude from Harvard College and was awarded the Harvard College Scholar Award for academic excellence. She received her medical degree from Columbia University College of Physicians and Surgeons and subsequently trained at New York University School of Medicine, one of the nation's top dermatology programs, where she was selected to be chief resident. Following residency, she completed a prestigious fellowship in Mohs micrographic surgery and dermatologic oncology with a focus on advanced reconstruction under the tutelage of one of the leaders in the field at Mount Sinai Hospital in New York. She serves as a reviewer for and her research has been published in premier peer-reviewed journals including Journal of the American Academy of Dermatology and Dermatologic Surgery. Dr. Ng joined the faculty of Johns Hopkins School of Medicine in 2017 and has been consistently recognized as a “Top Doctor” by Baltimore Magazine. Dr. Ng is rated as an Advanced provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Melanoma, and Bowen's Disease.

Dr. Sewon Kang is the Noxell Professor and Chairman of the Department of Dermatology at the Johns Hopkins University School of Medicine and the Dermatologist-in-Chief of Johns Hopkins Hospital. He is also founder and co-Director of the Cutaneous Translational Research Program (CTReP) at Hopkins. A recipient of the Dermatology Foundation's Career Development Award, he has received other research awards and grants from the American Dermatological Association, the National Psoriasis Foundation and the National Institutes of Health (Roadmap T32, K24, and R01). His research focus has been in the areas of skin pharmacology and photomedicine. He is the Past President of the Photomedicine Society, and the American Acne and Rosacea Society. Dr. Kang is or has been on the Board of Directors of multiple organizations including, the Society for Investigative Dermatology, the Association of Professors of Dermatology, the Dermatology Foundation, and the Skin of Color Society. An author on over 240 publications and book chapters, Dr. Kang is also the Editor-in-Chief of the 9th edition of the Fitzpatrick's Dermatology textbook. He is an inventor/co-inventor of 17 patents and has given over 300 presentations globally. A graduate with honors from Williams College and the University of Michigan, Dr. Kang completed dermatology residency and fellowship at the Harvard Medical School/Massachusetts General Hospital. He sees patients exclusively at the Johns Hopkins Hospital, and his areas of clinical expertise include photomedicine, skin cancer (melanoma), skin aging, and dermatology for ethnic skin. Dr. Kang is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Acne, Prurigo Nodularis, and Rosacea.

Dr. Janis Taube is a professor of dermatology and pathology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Her area of clinical expertise is dermatopathology. Dr. Taube serves as the Director of the Division of Dermatopathology and as the Assistant Director of the Dermatoimmunology Laboratory at the School of Medicine. Dr. Taube received her undergraduate degree in engineering from Duke University. She earned her M.D. from Tulane University and her M.Sc. in molecular medicine from University College London. She completed her residency in pathology at Johns Hopkins where she also served as the chief resident, before undertaking a dermatopathology fellowship at Stanford University. In 2009, Dr. Taube returned to Johns Hopkins for her certification in the Melanoma Clinic. She is one of the lead scientific researchers in the Department of Dermatology at Johns Hopkins. She has written over 180 peer-reviewed publications, and her research has been cited over 70,000 times. In addition to running her own research laboratory, she serves as the co-Director of the Mark Foundation Center for Advanced Genomics and Imaging and also as the co-Director of the Tumor Microenvironment Core Laboratory for the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Dr. Taube is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Pancreaticoduodenectomy.

Dr. Topalian is a physician-scientist whose studies of anti-tumor immunity have been foundational in developing cancer immunotherapy. She has published over 160 original research articles and reviews in this area and is one of the most highly cited researchers in the biomedical field. She received her medical and scientific training at Tufts University School of Medicine, Thomas Jefferson University Hospital, Children’s Hospital of Philadelphia and the National Cancer Institute. She joined the Johns Hopkins Kimmel Cancer Center in 2006 as the inaugural director of its Melanoma Program. Dr. Topalian is credited with advancing the clinical development of anti-PD-1 immunotherapy, and her work is widely recognized. She was named one of Nature’s 10 in 2014, and received the Karnofsky Award from ASCO in 2015, the Taubman Prize in 2016, the NCI’s Rosalind E. Franklin Award in 2018, the American Academy of Dermatology’s Gruber Memorial Cancer Research Award in 2020, and the Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges in 2021 for landmark discoveries in cancer immunotherapy. Dr. Topalian was elected to the National Academy of Medicine in 2017, and to the American Association for Cancer Research Academy in 2022. Her work has opened new avenues of scientific investigation and established immunotherapy as a pillar of oncology. Dr. Topalian is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Merkel Cell Carcinoma, Melanoma, Neuroendocrine Tumor, and Anal Cancer.

Dr. Julie Lange is an assistant professor of surgery, dermatology and oncology at the Johns Hopkins University School of Medicine. Dr. Lange was one of the original members of the Johns Hopkins melanoma group when it was first formed in 1995 and now serves as a clinical co-director of the Melanoma Program. Dr. Lange introduced the sentinel node technique to Johns Hopkins for both melanoma and breast cancer in the 1990s and has extensive experience with this technique. Dr. Lange is a graduate of the Vanderbilt University School of Medicine and completed her general surgery training at Yale-New Haven Hospital. She completed a fellowship in surgical oncology and immunotherapy at the Surgery Branch of the National Cancer Institute as well. Dr. Lange joined the faculty of the Department of Surgery at Johns Hopkins in 1994 and subsequently earned a Sc.M. in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. She has particular interest in melanoma at extremes of age, and in the factors associated with variance in melanoma care. Dr. Lange has published the largest study of melanoma in children, adolescents and young adults. She recognizes that melanoma in the older patient is a growing epidemic and has investigated the socioeconomic, demographic and healthcare factors that influence the treatment of melanoma in older persons. Dr. Lange is a member of the melanoma panel of the National Comprehensive Cancer Network, a group that annually evaluates and revises national treatment guidelines for melanoma. In 2015, she was inducted for her work into the Miller-Coulson Academy of Clinical Excellence, which recognizes outstanding clinicians at Johns Hopkins based on a number of factors, including communication and interpersonal skills, professionalism and humanism, a scholarly approach to clinical practice, and a passion for patient care. Dr. Lange is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Melanoma, Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Lymphadenectomy.

Dr. Jihad Mohamad Alhariri is an assistant professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include dermatology and medical dermatology. Dr. Alhariri received his undergraduate degree from the American University of Beirut. He earned his M.D. from the American University of Beirut and his M.P.H. from the Johns Hopkins University School of Public Health. He completed a residency in internal medicine at Good Samaritan Hospital of Maryland and a residency in dermatology at Johns Hopkins. Dr. Alhariri is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Melanoma, Hidradenitis Suppurativa, Giant Congenital Melanocytic Nevus, and Giant Congenital Nevus.

Dr. Kleinberg specializes in the radiation treatments, including stereotactic radiosurgery, of brain and spinal tumors. Areas of research include both tumors arising in the central nervous system and tumors metastasizing from other locations. He also specializes in the treatment of esophageal tumors and has led national clinical trials in both therapy of brain tumors as well as esophageal cancer. Dr. Kleinberg has been recently named in the US News and World Report list of top 1% of doctors in his specialty. He is the co-chair of the Eastern Cooperative Oncology Group Brain Tumor Working Group, Vice-Chair of the NCI Cooperative Group Steering Committee for Esophageal and Gastric Tumors, and is a member of the NCI Cooperative Group Steering Committee for Gastrointestinal Tumors. He is also on the American College of Radiation Oncology Neurologic Cancer Practice Accreditation Team. Make A Gift. Dr. Kleinberg is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Hepato-Pancreato-Biliary Surgery, and Gamma Knife Radiosurgery.

Petr Hausner is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Hausner is rated as a Distinguished provider by MediFind in the treatment of Melanoma. His top areas of expertise are Pseudomyxoma Peritonei, Colorectal Cancer, Familial Colorectal Cancer, and Anal Cancer. Dr. Hausner is currently accepting new patients.

Maie John is an Otolaryngologist in Baltimore, Maryland. Dr. John is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Melanoma, Glossectomy, and Gastrostomy.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Melanoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Paul Ringelman is a Plastic Surgeon in Baltimore, Maryland. Dr. Ringelman is rated as an Advanced provider by MediFind in the treatment of Melanoma. His top areas of expertise are Epidural Lipomatosis, Melanoma, Basal Cell Skin Cancer, and Squamous Cell Skin Carcinoma.